Evoke Pharma EBITDA vs. Price To Earning
| EVOK Stock | USD 4.08 0.19 4.45% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -7.3 M | Current Value -7.7 M | Quarterly Volatility 3.8 M |
For Evoke Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Evoke Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Evoke Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Evoke Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Evoke Pharma over time as well as its relative position and ranking within its peers.
Evoke |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share 7.792 | Quarterly Revenue Growth 0.698 | Return On Assets (0.34) | Return On Equity (3.50) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Evoke Pharma Price To Earning vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Evoke Pharma's current stock value. Our valuation model uses many indicators to compare Evoke Pharma value to that of its competitors to determine the firm's financial worth. Evoke Pharma is rated below average in ebitda category among its peers. It is rated below average in price to earning category among its peers . The company's current value of EBITDA is estimated at (7.66 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Evoke Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Evoke Price To Earning vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Evoke Pharma |
| = | (7.29 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Evoke Pharma |
| = | (3.21) X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Evoke Price To Earning Comparison
Evoke Pharma is currently under evaluation in price to earning category among its peers.
Evoke Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Evoke Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Evoke Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Evoke Pharma's change in net profit over the period of time. It can combine multiple indicators of Evoke Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -7.4 M | -7.8 M | |
| Income Before Tax | -7.8 M | -8.2 M | |
| Total Other Income Expense Net | -361.4 K | -343.3 K | |
| Net Loss | -7.8 M | -8.2 M | |
| Income Tax Expense | -7.4 M | -7.1 M | |
| Net Loss | -7.6 M | -8 M | |
| Non Operating Income Net Other | 390.1 K | 409.6 K | |
| Net Loss | -7.4 M | -7.8 M | |
| Interest Income | 144.6 K | 74.9 K | |
| Net Interest Income | -355.4 K | -373.1 K | |
| Change To Netincome | 1.7 M | 1.6 M | |
| Net Loss | (27.97) | (29.37) | |
| Income Quality | 0.64 | 0.98 | |
| Net Income Per E B T | 0.89 | 0.81 |
Evoke Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Evoke Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Evoke Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Evoke Pharma's important profitability drivers and their relationship over time.
Use Evoke Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evoke Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evoke Pharma will appreciate offsetting losses from the drop in the long position's value.Evoke Pharma Pair Trading
Evoke Pharma Pair Trading Analysis
The ability to find closely correlated positions to Evoke Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evoke Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evoke Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evoke Pharma to buy it.
The correlation of Evoke Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evoke Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evoke Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evoke Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Evoke Pharma position
In addition to having Evoke Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Information Technology ETFs Thematic Idea Now
Information Technology ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Information Technology ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Information Technology ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
To fully project Evoke Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Evoke Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Evoke Pharma's income statement, its balance sheet, and the statement of cash flows.